Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
1218.61.01041 Boehringer Ingelheim Investigational Site
mi
from
Tyler, TX
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
1218.61.01041 Boehringer Ingelheim Investigational Site
mi
from
Tyler, TX
Click here to add this to my saved trials
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
1245.25.10185 Boehringer Ingelheim Investigational Site
mi
from
Bountiful, UT
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
1245.25.10185 Boehringer Ingelheim Investigational Site
mi
from
Bountiful, UT
Click here to add this to my saved trials
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
527.82.180 Boehringer Ingelheim Investigational Site
mi
from
Layton, UT
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
527.82.180 Boehringer Ingelheim Investigational Site
mi
from
Layton, UT
Click here to add this to my saved trials
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
527.82.174 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, UT
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
527.82.174 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, UT
Click here to add this to my saved trials
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated:  1/8/2013
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Status: Enrolling
Updated: 1/8/2013
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative site
mi
from
Gainesville, GA
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Chicago, IL
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Beach Grove, IN
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Beach Grove, IN
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative site
mi
from
Boston, MA
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Omaha, NE
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Mineola, NY
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Blue Bell, PA
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Knoxville, TN
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative site
mi
from
Dallas, TX
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated:  1/9/2013
Novartis Investigative Site
mi
from
Spokane, WA
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome
Status: Enrolling
Updated: 1/9/2013
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Vitamin D for Painful Nocturnal Leg Cramps
Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem
Status: Enrolling
Updated:  1/14/2013
University of Wisconsin
mi
from
Madison, WI
Vitamin D for Painful Nocturnal Leg Cramps
Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem
Status: Enrolling
Updated: 1/14/2013
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Vitamin D and Adipose Tissue Inflammation
Vitamin D and Adipose Tissue Inflammation
Status: Enrolling
Updated:  1/15/2013
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Vitamin D and Adipose Tissue Inflammation
Vitamin D and Adipose Tissue Inflammation
Status: Enrolling
Updated: 1/15/2013
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Miller Children's Hospital
mi
from
Long Beach, CA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of California, Davis, M.I.N.D. Institute
mi
from
Sacramento, CA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of California, Davis, M.I.N.D. Institute
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Psychiatric Centers at San Diego
mi
from
San Diego, CA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Psychiatric Centers at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of Colorado Denver, Children's Hospital
mi
from
Aurora, CO
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of Colorado Denver, Children's Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of Miami, Mailman Center for Child Development
mi
from
Miami, FL
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of Miami, Mailman Center for Child Development
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Lake Mary Pediatrics
mi
from
Orange City, FL
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Lake Mary Pediatrics
mi
from
Orange City, FL
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Emory University School of Medicine
mi
from
Atlanta, GA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Kansas University Clinical Research Center
mi
from
Fairway, KA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Kansas University Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Kennedy Krieger Institute
mi
from
Baltimore, MD
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of Massachusetts
mi
from
Worcester, MA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Children's Hospital of Michigan
mi
from
Detroit, MI
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders
mi
from
Columbia, MO
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders
mi
from
Columbia, MO
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
New York State Institute for Basic Research in Developmental Disabilities
mi
from
Staten Island, NY
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
New York State Institute for Basic Research in Developmental Disabilities
mi
from
Staten Island, NY
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Duke Clinical Research Unit
mi
from
Durham, NC
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Duke Clinical Research Unit
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Akron Children's Hospital
mi
from
Akron, OH
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
University of Oklahoma, Physician's Child Study Center
mi
from
Oklahoma City, OK
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
University of Oklahoma, Physician's Child Study Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Suburban Research Associates/Elwyn Genetics
mi
from
Media, PA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Suburban Research Associates/Elwyn Genetics
mi
from
Media, PA
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Greenwood Genetics Center
mi
from
Greenwood, SC
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Greenwood Genetics Center
mi
from
Greenwood, SC
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Vanderbilt Kennedy Center
mi
from
Nashville, TN
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Vanderbilt Kennedy Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Children's Medical Center of Dallas
mi
from
Dallas, TX
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Red Oaks Psychiatry Associates, P.A.
mi
from
Houston, TX
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Red Oaks Psychiatry Associates, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Texas Children's Hospital
mi
from
Houston, TX
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Road Runner Research
mi
from
San Antonio, TX
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Road Runner Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated:  1/22/2013
Seattle Children's Hospital
mi
from
Seattle, WA
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
Status: Enrolling
Updated: 1/22/2013
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Status: Enrolling
Updated:  1/23/2013
Department of Medicine, University of California
mi
from
Irvine, CA
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Status: Enrolling
Updated: 1/23/2013
Department of Medicine, University of California
mi
from
Irvine, CA
Click here to add this to my saved trials